Exploring Growth Opportunities in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

Overview and Scope
Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.

Sizing and Forecast
The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%.  The  growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.

The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%.  The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Segmentation & Regional Insights
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza
2) By Route Of Administration: Oral; Injection; Inhalation
3) By End User: Hospitals; Specialty Clinics; Other End Users

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2023. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

Major Driver Impacting Market Growth
An increase in the number of respiratory diseases is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory diseases are disorders that affect the lungs and the respiratory system, leading to breathing difficulties and impaired lung function. Alpha-1 antitrypsin deficiency augmentation therapy aims to treat respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. The therapy works by restoring the balance of protease-antiprotease activity in the lungs, protecting lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the increase in the number of respiratory diseases propels the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Key Industry Players
Major players in the alpha-1 antitrypsin deficiency augmentation therapy market are  Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

The alpha-1 antitrypsin deficiency augmentation therapy market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Related Reports:

https://goodprnews.com/anoscope-market-forecast/
https://goodprnews.com/dumping-syndrome-market-outlook/
https://topprnews.com/anoscope-market-opportunities/
https://topprnews.com/understanding-industry-dynamics-insights-into-dumping-syndrome-market-growth/

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model